Sugi Predict

Sugi Predict / Compounds / SCHEMBL5228931

SCHEMBL5228931

SCHEMBL5228931

CC(C)N(c1nn(-c2ccc(NC(=O)c3ccccc3)cc2)cc1C(=O)O)C(=O)[C@H]1CC[C@H](C)CC1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 7/20 0.41
▸ KMT2A Q03164 7/20 0.41
▸ SMN1; SMN2 Q16637 5/20 0.41
▸ KDM5B Q9UGL1 1/20 0.41
▸ RAB9A P51151 6/20 0.40
▸ MAPT P10636 7/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ GAA P10253 1/20 0.40
▸ TP53 P04637 2/20 0.39
▸ HTT P42858 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ AURKA O14965 4/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5228937 1.00 MEN1 (0.41) MEN1KMT2ASMN1; SMN2KDM5BRAB9A
SCHEMBL5230027 0.97 MEN1 (0.41) MEN1KMT2ASMN1; SMN2KDM5BRAB9A
SCHEMBL5230020 0.97 MEN1 (0.41) MEN1KMT2ASMN1; SMN2KDM5BRAB9A
SCHEMBL5232510 0.93 KMT2A (0.44) MEN1KMT2ASMN1; SMN2RAB9AMAPT
SCHEMBL5230244 0.93 KMT2A (0.44) MEN1KMT2ASMN1; SMN2RAB9AMAPT
SCHEMBL5234022 0.93 KMT2A (0.44) MEN1KMT2ASMN1; SMN2RAB9AMAPT
SCHEMBL5230254 0.93 KMT2A (0.44) MEN1KMT2ASMN1; SMN2RAB9AMAPT
SCHEMBL5235260 0.92 NPC1 (0.42) MEN1KMT2ASMN1; SMN2KDM5BRAB9A
SCHEMBL5235257 0.92 NPC1 (0.42) MEN1KMT2ASMN1; SMN2KDM5BRAB9A
SCHEMBL14459907 0.91 MAPT (0.50) MEN1KMT2ASMN1; SMN2RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730116-B1 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORP (US) 2007-09-05 — — EP claimed
EP-1730116-B1 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORP (US) 2007-09-05 — — EP disclosed
US-20070167507-A1 4-Carbox pyrazole derivatives useful as anti-viral agents GLAXO GROUP LIMITED (GB) 2007-07-19 — — US disclosed
US-20070167507-A1 4-Carbox pyrazole derivatives useful as anti-viral agents GLAXO GROUP LIMITED (GB) 2007-07-19 — — US disclosed
US-20070167507-A1 4-Carbox pyrazole derivatives useful as anti-viral agents GLAXO GROUP LIMITED (GB) 2007-07-19 — — US disclosed
EP-1730116-A1 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2006-12-13 — — EP disclosed
WO-2005092863-A1 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2005-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167507-A1 4-Carbox pyrazole derivatives useful as anti-viral agents HAVCR2, RPL35, ZC3HAV1L MEN1 4820/4885KMT2A 4445/4885SMN1; SMN2 3430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.